- Mereo BioPharma Group said it had completed patient enrollment for a clinical study into a treatment for osteogenesis imperfecta, an orphan genetic disorder known as brittle bone disease.

A total of 112 adult patients had been enrolled into the dose-finding study, which was being conducted in the US and Europe.

The study had four arms and included an open-label arm expected to report six-month data on the top dose in the first half of 2019 and 12-month data in the second half of 2019.

Top-line 12-month data from the blinded dose ranging part of the study was expected in the fourth quarter of 2019.

'This is another important milestone in the development of BPS-804 for Osteogenesis Imperfecta (OI), which is a serious, debilitating and painful orphan disease for which there are currently no EMA or FDA approved treatments,' chief medical officer Alastair Mackinnon said.

'We believe BPS-804's mechanism of action is specifically suited to OI and has the potential to become a novel treatment option that could reduce fractures and improve quality of life of these patients.'

'We look forward to announcing data from this study during the course of 2019.'

At 9:51am: [LON:MPH] Mereo Biopharma Group Ltd share price was 0p at 226p

Story provided by